Intermittent interleukin-2 (IL-2) therapy has been shown to increase the number of CD4؉ T cells, preferentially cells with a naive phenotype, in patients with HIV infection. For this report we investigated the mechanism underlying this expansion by studying the relative roles of peripheral expansion and thymic output. In a cohort of six patients receiving IL-2 over a period of 1 year, the mean number of naive CD4؉ T cells increased from 139 to 387 cells per l while levels of T cell receptor rearrangement excision circles (TRECs) declined from 47,946 to 26,510 copies per 10 6 naive T cells, thus making it unlikely that the CD4؉ T cell count increases were secondary to increase in thymic output. To examine directly the impact of IL-2 on peripheral expansion, peripheral blood mature, naive CD4؉ T cells were labeled ex vivo with 5-bromodeoxyuridine as well as stained directly for Ki67. These studies revealed a 7-fold increase in the percentage of 5-bromodeoxyuridine-positive cells and a 20 -40-fold increase in Ki67 staining in the naive CD4؉ T cell pool in the setting of IL-2 administration. This degree of increase in mature CD4؉ T cell turnover induced by IL-2 does not compromise the future replicative potential of these cells, because longitudinal measurements of telomere length went from 6,981 to 7,153 bp after 1 year of IL-2 therapy. These data strongly suggest that much of the increase in CD4؉ cells associated with IL-2 treatment is caused by peripheral expansion of existing naive CD4؉ T cells rather than increased thymic output and that these increases occur without compromising the potential of these cells for further cell division.
I
n healthy individuals, relatively constant numbers of peripheral T cells are maintained by the death of mature T cells, the proliferation of existing T cells, and generation of new T cells by thymopoiesis. HIV infection perturbs this homeostatic balance and over a period of years leads to decline in the number of CD4ϩ T cells. This process leads to immunodeficiency and increased susceptibility to opportunistic infections (1) . The reason for the progressive loss of CD4ϩ T cells in HIV-infected patients is not understood fully, although many hypotheses have been proposed (2) . The currently licensed antiretroviral reagents for treating HIV infection decrease viral load and lead to increases in CD4ϩ T cell number. One experimental approach that can increase the CD4ϩ T cell pool in HIV patients independent of significant effect on viral load is treatment with the T cell growth factor IL-2 (3, 4) . Several studies have established that intermittent administration of IL-2 increases the number and percentage of CD4ϩ T cells in HIV-1-infected patients. The clinical benefit of this increase is unknown and is currently the focus of two phase-III studies, study of IL-2 in people with low CD4ϩ T cell counts on active anti-HIV therapy (SILCAAT) and the evaluation of subcutaneous proleukin in a randomized international trial (ESPRIT) (3, 5) .
The underlying mechanism by which IL-2 treatment increases CD4ϩ T cells is not understood fully (4) . Possibilities include increased production, by enhanced stem cell differentiation or increased peripheral expansion, and decreased destruction. Although the thymus may involute with age, recent data suggest that it can retain functional activity in adults (6) . During maturation in the thymus, cells destined to become T cells undergo the rearrangement of their T cell receptor genes by site-specific somatic DNA-recombination events, leading to the formation of extrachromosomal circular excision products as a by-product. These episomes, T cell receptor rearrangement excision circles (TRECs), are stable and persist in the newly matured T cells. They do not replicate during cell division and thus are diluted during mitosis of these cells or lost when these cells die (7) . Recently, Douek et al. (8) have developed a method to quantitate TRECs present in human T cells. Enumeration of the number of cells harboring TRECs is considered to be a direct measure of thymic emigrants. However, interpretation of such data also requires concomitant assessment of T cell division. In addition to thymopoiesis, T cells can be produced through the peripheral expansion of existing T cells. To assess the relative contribution of these two mechanisms of increased T cell production to the CD4ϩ T cell expansions seen in the setting of IL-2 therapy, we quantitated the changes in TREC levels and rates of turnover by Ki67 staining and BrdUrd incorporation in naive CD4ϩ lymphocytes during IL-2 therapy. Ki67 acts as a marker of activation and is increased from late G 1 forward in the cell cycle, whereas BrdUrd incorporation is a direct measurement of the fraction of cells that have entered S phase during the time of labeling. The results suggest that much of the increase in CD4ϩ T cells associated with IL-2 treatment is caused by peripheral expansion of existing cells rather than increased thymic output.
Materials and Methods
Patients. Cryopreserved or freshly isolated peripheral blood mononuclear cells (PBMCs) from HIV-infected participants enrolled in National Institute of Allergy and Infectious Diseases Institutional Review Board-approved protocols were used. The patients studied longitudinally were selected from a cohort of 31 patients enrolled in a randomized controlled trial of IL-2 in patients with HIV infection. They were selected based on the criteria of (i) adequate numbers of cryopreserved cells for study, (ii) a clear increase in CD4ϩ T cell count in response to IL-2, and (iii) viral loads Ͻ20,000 copies per ml at both time points for analysis. All participants in these analyses received IL-2 by continuous infusion for 5 days as described (9) . IL-2 cycles were administered approximately every 2 months, and the total number of cycles ranged from four to seven over a 12-month period. Day 0 denotes the blood collected immediately before beginning of the first IL-2 infusion, day 5 refers to blood collected at the end of the first IL-2 infusion, and week 48 refers to the sample taken 48 weeks from the start of the IL-2 therapy. The base-line and follow-up characteristics of the patients are shown in Table 1 . All patients were on a combination of two reverse-transcriptase inhibitors at the time of the study (1993) (1994) .
Immunophenotyping. Cryopreserved PBMCs from the same time point as the TREC analysis were stained with monoclonal antibodies for CD45RO APC (clone UCHL-1), CD27 FITC (clone L128), and CD4 PerCP (clone SK3) or CD8 PerCP (clone SK1), all from Becton Dickinson Immunocytometry Systems, for 20 min at 4°C in the dark. Samples were subsequently fixed with fluorescence-activated cell sorter (FACS) lysis solution (Becton Dickinson Immunocytometry Systems) for 10 min in the dark at room temperature and washed once with PBS͞0.5% BSA͞ 0.1%NaN 3 and analyzed on a four-color multiparameter flow cytometer (FACScalibur, Becton Dickinson Immunocytometry Systems). Intracellular staining for the nuclear antigen Ki67 was performed after surface staining. After fixation, cells were permeabilized for 10 min with FACS permeabilization solution (Becton Dickinson Immunocytometry Systems), subsequently stained with Ki67 PE antibody (clone B56, Becton Dickinson Immunocytometry Systems) for 30 min at 37°C in the dark, and washed twice with PBS͞0.5% BSA͞0.1%NaN 3 . Approximately 1.5-2 ϫ 10 5 total events and a minimum of 10,000 events in the CD4ϩ or CD8ϩ gate were collected per sample. FLOW JO software was used for all flow-cytometric data analysis (Tree Star, San Carlos, CA).
TREC Measurements. CD4ϩ and CD8ϩ T cells were obtained from frozen PBMCs by using magnetic beads (Dynabeads M-450 CD4, Dynabeads M-450 CD8, and detachaBead, Dynal, Great Neck, NY). TRECs in PBMCs and purified CD4ϩ and CD8ϩ cells were quantitated by real-time PCR using a cell-lysis method as described (10) . The consistency of the DNA content of the cell lysate was checked by real-time PCR using a ribosomal protein gene and the Taqman assay kit from Applied Biosystems. The number of TRECs per naive T cell was calculated by measuring the number of naive cells present in PBMCs by flow-cytometric analysis as described above. Naive T cells were defined as the pool of cells with CD4ϩCD45ROϪCD27ϩ and CD8ϩCD45ROϪCD27ϩ.
Measurement of Naive CD4؉ T Cell Proliferation. Ex vivo labeling of proliferating naive CD4ϩ T cells was carried out by incubating freshly isolated PBMCs with BrdUrd for 4 h at 37°C as described (11) . Labeled cells were analyzed by FACS. Samples obtained from a separate cohort of patients who were receiving IL-2 were used in these experiments.
Measurement of Telomeric Terminal Restriction Fragment (TRF)
Length. The TRF was measured by using a modification of the procedure by Feng et al. (12) . Genomic DNA was isolated from purified CD4ϩ T cells according to the manufacturer's recommended procedure (Puregene, Gentra Systems). Equal amounts of DNA were digested with AluI and HinFI, and 2 g per well were loaded onto a 1% agarose gel. DNA molecular weight standards (DNA Marker Analysis System, Life Technologies, Rockville, MD) were loaded every 10 -15 lanes to correct for uneven sample separation across the gel. DNA restriction fragments were resolved for 18 h at 15°C by field-inversion gel electrophoresis (FIGE Mapper Power Module, Bio-Rad) using a nonlinear switch-time ramp of 0.1-0.4 sec and a forward and reverse voltage gradient of 240 and 160 volts, respectively. The DNA was transferred to a nylon membrane (Hybond-NX, Amersham Pharmacia) and simul- CD4ϩ and CD8ϩ T cells were purified as described in Materials and Methods, and the amount of TRECs in these cells was quantitated. The number of naive cells present in CD4ϩ and CD8ϩ cells was estimated by immunostaining. Naive cells were defined as CD45ROϪ͞ CD27ϩ. Pre-and post-IL-2 refers to day-0 and week-48 samples, respectively.
was analyzed by using LAB WORK GEL ANALYSIS software (Ultraviolet Products, San Gabriel, CA), and average TRF length was calculated by using weighted mean calculations that normalize the signal intensity relative to the size of each digestion product (13) .
Results

Changes in CD4؉ T Cells in IL-2-Treated Patients.
Multiple randomized, controlled studies have shown that intermittent IL-2 treatment increases CD4ϩ T cell count in HIV-infected individuals. The mechanism responsible for these increases remain unclear (14) (15) (16) (17) (18) (19) . The six patients studied longitudinally in this report were from a cohort of IL-2-treated subjects described earlier from whom stored PBMCs were available for analysis (9, 14) . These patients received a total of 4-7 5-day IL-2 infusions during the study period of 12 months. During the IL-2 therapy, these patients were treated with a combination of two nucleoside reverse-transcriptase inhibitors, zidovudine and didanosine or zalcitabine (Table 1 ). On average CD4ϩ T cell numbers increased from a base-line count of 571 to 1,449 (P ϭ 0.01) in the group of six patients selected for this study. In all patients there was an increase in total and naive CD4ϩ T cells over the time period examined ( Fig. 1 and Table 1 ).
Decline in TREC Levels in T Cells of Patients Treated with Intermittent
IL-2.
Before the analysis of PBMC samples from IL-2-treated patients, TREC levels in purified naive (CD45RAϩ) and memory (CD45ROϩ) cells from four HIV-1-positive patients were quantitated by real-time PCR method. In all these samples, greater than 97% of the total TRECs were present in naive cells (data not shown). These results confirmed earlier observations that the vast majority of the TRECs are present within naive T cells (8) . Based on this observation, TRECs present in PBMC samples from IL-2-treated patients were quantitated, and the data were expressed as the number of TRECs per million naive T cells (Fig. 2) . Compared with base-line, the concentration of TRECs in the total naive T cell pool (CD4 and CD8) decreased (P ϭ 0.02) by an average of 57% over 12 months.
IL-2 treatment preferentially increases the number of naive CD4ϩ T cells and has a minimal effect on CD8ϩ T cell number ( Fig. 1 and Table 2 ). To understand better the potential role of the thymus in this preferential effect of IL-2 on CD4ϩ T cell expansion, the levels of TRECs were measured in purified CD4ϩ and CD8ϩ cells from all three patients from whom enough frozen cells were available. The drop in the level of TRECs was caused predominantly by changes in the concentration of TRECs in CD4ϩ cells. Minimal changes were seen within the CD8ϩ T cells. TREC concentrations declined by an average of 76 Ϯ 13% in CD4ϩ T cells and 1 Ϯ 18% in CD8ϩ T cells ( Table 2 ). The decline in the concentration of TRECs in CD4ϩ T cells along with the increase in the total number of naive CD4ϩ T cells suggest that the naive CD4ϩ T cell expansions in IL-2-treated patients are caused, in large part, by an increased proliferation of mature naive T cells.
Increased Proliferation of Naive CD4؉ T Cells in IL-2-Treated Patients.
To evaluate directly the proliferation of mature, naive CD4ϩ T cells in the setting of IL-2 therapy, the percentage of Ki67ϩ cells was measured immediately after a course of IL-2 treatment (Fig.  3A) . The percentage of naive (CD45ROϪ͞CD27ϩ) CD4ϩ T cells positive for Ki67 increased dramatically from values of 1-2% at day 0 to more than 40% on day 6 of IL-2 treatment. Interestingly, 2 months after an IL-2 cycle the percentage of Ki67ϩ CD4ϩ naive cells declined after this initial increase to levels below base-line values. Similar increases and declines in the percentage of CD4ϩKi67ϩ cells were seen in all six patients studied. Overall the percentage of naive CD4ϩ T cells that was Ki67-positive increased from 1.3 Ϯ 0.4% at day 0 to 46 Ϯ 5% at day 6 of an IL-2 cycle and declined to 0.5 Ϯ 0.1% at 1 year.
Another way to examine directly naive CD4ϩ T cell proliferation is to determine the percentage of cells entering S phase through use of a marker of DNA synthesis such as BrdUrd. Direct examination of the ex vivo proliferation of the CD4ϩ͞ CD45ROϪ T cell subset by labeling with BrdUrd for 4 h immediately after isolation revealed a 6-7-fold increase (P ϭ 0.002) in the percentage of cells in S phase at the end of an IL-2 cycle (Fig. 3B) . Thus, in IL-2-treated patients the declines in TREC values are accompanied by short-term increases in the proliferation of naive CD4ϩ cells as indicated by Ki67 staining and BrdUrd labeling. These data indicate that IL-2-induced proliferation of naive T cells is likely a major mechanism leading to the increases in naive CD4ϩ T cells seen with IL-2 therapy.
IL-2-Induced Proliferation of Naive CD4؉ T Cells Does Not Lead to
Shortening of Telomeres. A major concern about the renewal of CD4ϩ T cells by continued proliferation of existing cells in HIV-1-infected patients is that these cells might reach a stage of replicative senescence and not be able to divide further after a certain length of time and number of cycles. Lengths of telomeres present at the end of a chromosome can be used as a marker of the proliferative potential of eukaryotic cells (20, 21) . The average telomere lengths of CD4ϩ cells from IL-2-treated patients were estimated by TRF-length analysis (Fig. 4) . There was no difference in the average TRF length between CD4ϩ 
Discussion
In addition to viral suppression, a major objective of the treatment of patients with HIV infection is to restore and preserve immune function. IL-2, a T cell growth factor that plays a major role in T cell activation and proliferation, is being administered as an experimental treatment of HIV-1-infected individuals with this objective (3) (4) (5) . The group of patients analyzed in this study experienced a 2-fold increase in their CD4ϩ T cell counts after 1 year of IL-2 treatment. In prior studies it has been demonstrated that IL-2 treatment leads to preferential expansion of naive CD4ϩ cells in HIV-1-infected patients (18) . However, the underlining mechanisms by which IL-2 increases CD4ϩ T cells are not understood (3, 19, 22) . The increase could be caused by the proliferation of existing cells, enhanced survival of existing cells, de novo production of naive cells by the thymus, or a combination of these factors. The present study demonstrates that peripheral expansion of mature naive CD4ϩ T cells is a major in vivo activity of IL-2 (Fig. 5) .
During maturation in the thymus, T cells undergo the rearrangement of their T cell receptor genes, resulting in the formation of stable episomal TRECs that persist in the newly matured T cells and are diluted out during mitosis of these cells or lost when these cells die. A number of studies have shown that TREC levels decline with HIV infection and increase after treatment with highly active antiretroviral therapy, suggesting that changes in viral replication can lead also to changes in levels of TRECs (8, 9, (23) (24) (25) . Recent data suggest that the decline in TREC levels in HIV patients may be caused by increased cell division associated with immune activation by HIV rather than a decrease in thymic function (11, 26) . Similarly the increased level of TRECs seen in patients treated with the highly active antiretroviral therapy may be caused by reduced immune activation and proliferation rather than an increase in the number of T cells with TRECs entering the periphery from the thymus (11, 24) . In this regard it may be more accurate to refer to TREC-containing cells as ''primary'' rather than "recent" thymic emigrants.
In the IL-2-treated patients studied here, increases in the total numbers of naive CD4ϩ T cells were associated with decreases in the concentration of TRECs. We believe the most likely explanation for this observation is a dilution of TRECs caused by increased proliferation. This conclusion is supported by the short-term increases in in vivo and ex vivo proliferation of naive CD4ϩ cells from IL-2-treated patients as indicated by independent examinations of Ki67 and BrdUrd staining. Interestingly, IL-2 administration is accompanied by an increase in the levels of tumor necrosis factor ␣ (TNF␣) and IL-6, a cytokine milieu that, along with IL-2, has been shown to promote the growth of naive CD4ϩ T cells in vitro (27, 28) . Decreased death and increased half-life also may contribute to the long-term raise in naive CD4ϩ T cells seen in IL-2-treated patients. This is suggested by the lower levels of Ki67 staining seen in these cells after 1 year of IL-2 therapy.
Telomeric DNA sequences that are present at the extreme ends of chromosomes shorten progressively during each division of the eukaryotic cells. The telomere length not only serves as an indicator of the replicative history of a cell but also as a determining factor for the residual replicative capacity of the cell. It has been shown earlier that there is no change or a slight increase in telomere length of CD4ϩ T cells in HIV patients (29, 30) . Despite that observation, a major concern about the IL-2-mediated increase in the proliferation of naive CD4ϩ cells is that it may result in the exhaustion of renewal capacity of these cells, leading to premature senescence. In the present study, the telomere lengths in IL-2-treated patients showed no significant changes during the course of 1 year, during which time the CD4ϩ T cell number doubled. Given that peripheral expansion plays a role in that doubling, it seems possible that IL-2-induced expansions may be associated with the induction of telomerase. These data indicate that the CD4ϩ T cells induced by IL-2 treatment retain their full replicative potential, suggesting that IL-2 along with highly active antiretroviral therapy can be used successfully to increase and maintain normal levels of CD4ϩ T cells in HIV-infected subjects.
We thank Dr. A. S. Fauci for his ongoing guidance and support, Dr. D. C. Douek for help in the TREC assay, and Ms. Mary Rust for her editorial Fig. 5 . IL-2 exerts multiple effects on the CD4ϩ T cell pool. New cells may enter the pool via homeostatic-driven proliferation or via stem cell differentiation through a thymic environment. During the time of an IL-2 cycle there is a pronounced increase in the size of the pool caused by peripheral expansion as indicated by decreases in TREC levels and increases in Ki67 expression and spontaneous BrdUrd incorporation. After IL-2 an increase in the CD4ϩ T cell pool is maintained. We postulate that persistent increases in the CD4ϩ T cell pool result from a state of decreased turnover and increased cell survival.
